DVA Day at AMP 2024

AMP offers an unparalleled experience tailored for CLI specialists. This event will deliver a unique blend of CLI education and vibrant interactions among faculty and attendees, offering an impactful and inspiring event that you cannot miss. 

This year, we are introducing a dedicated day of programming focused on deep vein arterialization (DVA). Included with your main conference registration or offered as a single-day event, DVA Day grants you comprehensive access to: 

  • Key topics covering DVA patient selection and outcomes, tools and techniques, surveillance, and wound management.
  • 4+ CME/CNE credits.

Why is DVA Education Important?

DVA education is crucial for clinicians because it expands their treatment options for patients with critical limb ischemia (CLI) and end-stage plantar disease. By understanding the principles, indications, and outcomes associated with DVA, clinicians can offer their patients a potentially limb-saving alternative to amputation. This knowledge enables clinicians to choose the appropriate time to initiate the process, optimize patient selection for DVA, and collaborate effectively with other providers like wound care specialists and podiatrists to provide comprehensive care. Ultimately, DVA education empowers clinicians to deliver patient-centered care that prioritizes limb salvage and preserves the patient’s quality of life.

DVA Day Agenda

Saturday, August 17, 2024

7:00 AM - 8:00 AM Live Case Breakfast Symposium (non-accredited)
Operator: Pradeep Nair, MD, FACC, FSCAI
This non-accredited/non-approved for CECH activity is sponsored by Philips.

8:30 AM - 10:05 AM Session 12: DVA Introduction, Patient Selection & Outcomes

  • Deep Vein Arterialization: History and Rationale
  • Fluoroscopic and Ultrasound Criteria for Patient Selection in DVA
  • From Rest Pain to Rutherford Class 6: What is the Ideal Time to Perform a pDVA?
  • What are the Common Clinical Risk Factors in CLI Patients That May Require DVA?
  • Open vs Endo Arterializations - When To Do What?
  • Clinical Outcomes with FDA-Approved LimFlow System
  • Outcomes Data for Off-the-Shelf DVA
  • Noninvasive and Invasive Imaging Assessment for Patients with DVA
  • Which Tibial Vessel Should You Choose for Percutaneous DVA?
  • DVA Reimbursement and Payment Horizons
  • Panel Discussion

10:20 AM - 12:00 PM Session 13: DVA Tools & Techniques

  • Percutaneous DVA Tools – The Limflow System
  • Off the Shelf pDVA Tools
  • Step-by-Step DVA Case
  • Current and Future Methods for Creating Percutaneous AV Fistulas
  • Superficial Venous Arterialization
  • Choosing the Method of Revascularization in the Arterial and Venous Conduits?
  • Patterns of DVA Failure: When Is Reintervention Appropriate?
  • Delivery of Self-Expanding Covered Stents in pDVA: Tips and Tricks
  • Management of Venous Conduit Revascularization Including the Venous Pedal Loops
  • Timing, Types and Reasons for Repeat Interventions
  • Proximal vs Distal DVA Including Plantar DVA
  • Panel Discussion

12:00 PM - 12:30 PM Lunch

12:30 PM - 1:30 PM Lunch Symposium (non-accredited): PROMISE Delivered: From No Option to Limb Salvage with LimFlow
Speakers: Miguel Montero-Baker. MD; Daniel Clair, MD; Michael Siah, MD; Elizabeth Genovese, MD, MS, FACS, RPVI
This non-accredited/non-approved for CECH activity is sponsored by Inari Medical. 

2:00 PM - 3:00 PM Session 14: Surveillance & Wound Management

  • Noninvasive Monitoring Post DVA
  • What to Expect Clinically in Patients Post-DVA? Normal vs Abnormal Findings
  • Surgical Management of Foot Wounds in Patients with pDVA. Ideal Time and Level of Minor Amputation
  • Appropriate Long-Term Anticoagulation in Patients with pDVA
  • Hemodynamics and Perfusion Technology in pDVA
  • Managing New Venous Hypertension Wounds
  • Guillotine vs Flap Closure
  • Avoiding Unwarranted Amputation in Post-DVA Patients Due to Lack of Awareness by Other Healthcare Providers
  • Panel Discussion
  • This DVA course day is the first to provide a complete practical review of this technology empowering physicians to guide treatment for patients with end-stage CLI.

    Fadi Saab, MD, FASE, FACC, FSCAI